Kim G. Dadlani

Photo of

Dadlani

Outstanding Alumni Achievement Award, 2012

After earning a B.B.A. and MBA from Western Michigan University, Kim Dadlani leveraged his skills to take on progressively more responsible positions, with the majority of his career spent in the pharmaceutical industry.

Dadlani began his career at Upjohn Corporation where he held the roles of senior financial consultant and director of global executive compensation. He then became finance director of pharmaceutical business for Upjohn—a role he continued with Pharmacia.

Dadlani’s next role at Pharmacia was vice president of finance and business technology for animal health. In that role, his work in strategic planning and in financial planning and analysis enhanced forecasting capacity, enabled the unit to consistently exceed quarterly earnings targets and yielded performance that was above industry averages. He then assumed the role of vice president of finance for global specialty businesses where he continued his excellent financial management and served in key leadership capacities.

Next, Dadlani became vice president of finance and corporate insurance at Pfizer where he led the finance groups that supported all corporate groups—legal, business technology, human resources, business development, finance, facilities, procurement and corporate affairs. In addition, he was responsible for the corporate insurance group. He provided the financial leadership for management of an $8 billion operating budget and oversaw a staff of 110 personnel. A member of the CFO counsel and the finance leadership team, he implemented best-in-class financial processes for planning, forecasting and management reporting.

Dadlani became known for innovation, organizational re-engineering and change management that significantly affected the bottom line at Pfizer. He led the working capital team which resulted in annual cash flow improvement of $1 billion. He spearheaded key initiatives in the legal division, resulting in cost reductions of 30 percent or $300 million. He was also responsible for several other initiatives that resulted in millions of dollars in cost savings.

Retiring in 2011, Daldani’s 30-year distinguished career in the pharmaceutical industry is a master class in being a change agent and risk taker who identifies growth opportunities. He also thrived in new cultures resulting from mergers, acquisitions and restructuring and played a key role in integrating acquired companies’ cost structures and delivering on the aggressive cost savings targets.